• Publications
  • Influence
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy
TLDR
These revised definitions of invasive fungal disease are intended to advance clinical and epidemiological research and may serve as a useful model for defining other infections in high-risk patients. Expand
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.
TLDR
Emphasis has been placed on potential complications in management of cryptococcal infection, including increased intracranial pressure, immune reconstitution inflammatory syndrome (IRIS), drug resistance, and cryptococcomas. Expand
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.
During the past several decades, there has been a steady increase in the frequency of opportunistic invasive fungal infections (IFIs) in immunocompromised patients. However, there is substantialExpand
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
TLDR
In patients with invasive aspergillosis,Initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B. Expand
Epidemiology and clinical manifestations of mucormycosis.
TLDR
The emerging epidemiology and the clinical manifestations of mucormycosis are described and this disease is increasingly recognized in recently developed countries, such as India, mainly in patients with uncontrolled diabetes or trauma. Expand
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
TLDR
This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia. Expand
Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis
Whole-exome sequencing reveals activating STAT1 mutations in some patients with autosomal dominant chronic mucocutaneous candidiasis disease.
Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients.
TLDR
It is concluded that an initial assessment of PAN or CSS severity enables outcome and mortality to be predicted and the FFS is a good predictor of death and can be used to help the clinician choose the most adequate treatment. Expand
Standards and standardization in mastocytosis: Consensus Statements on Diagnostics, Treatment Recommendations and Response Criteria
TLDR
Recommendations and algorithms should greatly facilitate the management of patients with mastocytosis in clinical practice, selection of patients for therapies, and the conduct of clinical trials. Expand
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research
TLDR
These updated definitions of IFDs should prove applicable in clinical, diagnostic, and epidemiologic research of a broader range of patients at high-risk. Expand
...
1
2
3
4
5
...